In an editorial in the December 1 issue, JAMA Editor-in-Chief, Catherine D. DeAngelis, M.D., M.P.H., Executive Deputy Editor, Phil B. Fontanarosa, M.D., and Deputy Editor Drummond Rennie, M.D., write "Physicians and patients expect that when medications are prescribed correctly for labeled indications and are used as directed, these medications generally will have beneficial effects and will not cause significant harm. This confidence in pharmaceutical products reflects trust in the effectiveness and integrity of the drug approval and monitoring process. However, the current approval process for drugs and biological agents in the United States has come under intense scrutiny, most notably because of concerns about influence from industry." The editorial, to be published in the December 1 issue of JAMA, is being released early online today because of its relevance to current events.

"To improve the necessary measures to monitor the safety of marketed drugs, the drug approval process must be decoupled from the postmarketing safety and surveillance system. It is unreasonable to expect that the same agency that was responsible for approval of drug licensing and labeling would also be committed to actively seek evidence to prove itself wrong (i.e., that the decision to approve the product was subsequently shown to be incorrect.) One option worth strong consideration, as others have suggested, is to establish an independent drug safety board or independent agency for drug safety, specifically to oversee postmarketing surveillance for drugs and devices." "Above all, the agency must be completely independent of influence from the pharmaceutical industry, biotechnology firms, and medical device manufacturers."

"The postmarketing surveillance system requires a long overdue major restructuring. Until that occurs as indicated by the articles in this issue of JAMA, as epitomized by recent evidence of serious harms from widely used and heavily promoted medi
'"/>

Contact: Jann Ingmire
312-464-2499
JAMA and Archives Journals
22-Nov-2004

Page: 1 2
Related medicine news :

1. Its high time we registered all clinical trials say editors of Lancet and BMJ
2. Hospital acquired infections present major problem for infants in developing countries
3. Study finds majority of women willing to accept cervical cancer vaccine for self and children
4. Serum sodium level is a major predictor of a poor prognosis for heart failure patients
5. Antimicrobials to prevent infection in major surgery are used properly only about half the time
6. New European cancer figures for 2004 major efforts needed against the big four killers
7. Penn joins major NCI research initiative to advance breast cancer therapies
8. Mayo Clinic discovers a key to low metabolism and major factor in obesity
9. National Academies news: Academy honors 17 for major contributions to science
10. Voluntary health organizations, publishers announce major information initiative
11. Survey suggests majority of women surgeons satisfied in their profession